Tempest Therapeutics exclusively licensed Senlang’s CD7-targeted lentiviral in vivo CAR-T platform, including lead BCMA/GPRC5D candidate TPST-4903, following initial Phase 1 results.
Market-relevant event
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
Tempest Therapeutics exclusively licensed Senlang’s CD7-targeted lentiviral in vivo CAR-T platform, including lead BCMA/GPRC5D candidate TPST-4903, following initial Phase 1 results.
Market-relevant event
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
https://www.stocktitan.net/news/TPST/tempest-reports-third-quarter-2026-financial-results-and-provides-n2hkfeek9rnh.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/TPST/tempest-reports-third-quarter-2026-financial-results-and-provides-n2hkfeek9rnh.html?utm_source=stocktitan-bluesky&utm_medium=social
💰 Por apenas R$232,85
🛒 Compre aqui: https://botvaro.com/l/tpsT?src=bs
⭐⭐⭐⭐☆ 4,3
🏪 Vendido por Amazon
Corre pra ver antes que acabe 💯
Acompanhe mais ofertas no nosso grupo:
lupagrupos.com
💰 Por apenas R$232,85
🛒 Compre aqui: https://botvaro.com/l/tpsT?src=bs
⭐⭐⭐⭐☆ 4,3
🏪 Vendido por Amazon
Corre pra ver antes que acabe 💯
Acompanhe mais ofertas no nosso grupo:
lupagrupos.com
On November 9, 2026, Tempest Therapeutics, Inc., a Delaware corporation held its 2026 Annual Meeting of Stockholders . The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth below.
On November 9, 2026, Tempest Therapeutics, Inc., a Delaware corporation held its 2026 Annual Meeting of Stockholders . The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth below.
https://www.stocktitan.net/news/TPST/tempest-therapeutics-exercises-option-to-license-senlang-s-cd7-u1x80eiplocj.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/TPST/tempest-therapeutics-exercises-option-to-license-senlang-s-cd7-u1x80eiplocj.html?utm_source=stocktitan-bluesky&utm_medium=social
💰 Por apenas R$238,92
🛒 Compre aqui: https://botvaro.com/l/tpsT?src=bs
⭐⭐⭐⭐☆ 4,3
🏪 Vendido por Amazon
Confere essa oportunidade 🛍️
Participe do nosso grupo:
lupagrupos.com
💰 Por apenas R$238,92
🛒 Compre aqui: https://botvaro.com/l/tpsT?src=bs
⭐⭐⭐⭐☆ 4,3
🏪 Vendido por Amazon
Confere essa oportunidade 🛍️
Participe do nosso grupo:
lupagrupos.com
On November 4, 2026, Tempest Therapeutics, Inc., a Delaware corporation , received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed bel...
On November 4, 2026, Tempest Therapeutics, Inc., a Delaware corporation , received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed bel...
Horn-Warnock Stephanie (CFO, Treasurer, & Corp Sec.) filed Form 3 reporting no initial stock ownership.
Horn-Warnock Stephanie (CFO, Treasurer, & Corp Sec.) filed Form 3 reporting no initial stock ownership.
Frederick John W. () reported special transactions (Non-P/S).
Frederick John W. () reported special transactions (Non-P/S).
Frederick John W. () initiated ownership with 8,000 shares upon appointment.
Frederick John W. () initiated ownership with 8,000 shares upon appointment.
Departure of Chief Financial Officer and Principal Financial and Accounting Officer On October 26, 2026, Ms. Constance Ames confirmed to Tempest Therapeutics, Inc. that she would be resigning from her position as Chief Financial Officer of the Company and from any and all other positions ...
Departure of Chief Financial Officer and Principal Financial and Accounting Officer On October 26, 2026, Ms. Constance Ames confirmed to Tempest Therapeutics, Inc. that she would be resigning from her position as Chief Financial Officer of the Company and from any and all other positions ...
Status Negosiasi: Usulan pembangunan dua jembatan layang (flyover) yang diajukan Pemkot Bekasi sebagai syarat perpanjangan kontrak lima tahun pengelolaan TPST Bantargebang belum masuk dalam draf Nota Kesepahaman (MoU)…
Status Negosiasi: Usulan pembangunan dua jembatan layang (flyover) yang diajukan Pemkot Bekasi sebagai syarat perpanjangan kontrak lima tahun pengelolaan TPST Bantargebang belum masuk dalam draf Nota Kesepahaman (MoU)…